TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5542.75M
Enterprise Value 3497.25M
Trailing P/E N/A
Forward P/E 1-7.26
PEG Ratio (5 yr expected) 1-0.17
Price/Sales (ttm)33.35
Price/Book (mrq)8.93
Enterprise Value/Revenue 330.56
Enterprise Value/EBITDA 6-3.47

Trading Information

Stock Price History

Beta (3Y Monthly) 2.27
52-Week Change 3-66.37%
S&P500 52-Week Change 36.70%
52 Week High 36.9400
52 Week Low 32.2000
50-Day Moving Average 32.6371
200-Day Moving Average 34.2330

Share Statistics

Avg Vol (3 month) 33.59M
Avg Vol (10 day) 32.01M
Shares Outstanding 5241.22M
Float 198.65M
% Held by Insiders 117.76%
% Held by Institutions 178.61%
Shares Short (Jun 28, 2019) 486.6M
Short Ratio (Jun 28, 2019) 420.04
Short % of Float (Jun 28, 2019) 449.27%
Short % of Shares Outstanding (Jun 28, 2019) 435.90%
Shares Short (prior month May 31, 2019) 486.63M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2100/1
Last Split Date 3Oct 3, 2011

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-882.51%

Management Effectiveness

Return on Assets (ttm)-58.88%
Return on Equity (ttm)-175.86%

Income Statement

Revenue (ttm)16.27M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)4.60%
Gross Profit (ttm)13.36M
EBITDA -143.27M
Net Income Avi to Common (ttm)-147.72M
Diluted EPS (ttm)-0.6390
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)122.88M
Total Cash Per Share (mrq)0.51
Total Debt (mrq)77.38M
Total Debt/Equity (mrq)127.50
Current Ratio (mrq)3.39
Book Value Per Share (mrq)0.25

Cash Flow Statement

Operating Cash Flow (ttm)-125.33M
Levered Free Cash Flow (ttm)-95.35M